ATE512224T1 - Rekonstituierter menschlicher anti-hm.1 antikörper - Google Patents

Rekonstituierter menschlicher anti-hm.1 antikörper

Info

Publication number
ATE512224T1
ATE512224T1 AT97942246T AT97942246T ATE512224T1 AT E512224 T1 ATE512224 T1 AT E512224T1 AT 97942246 T AT97942246 T AT 97942246T AT 97942246 T AT97942246 T AT 97942246T AT E512224 T1 ATE512224 T1 AT E512224T1
Authority
AT
Austria
Prior art keywords
chain
human
antibody
antibodies
region
Prior art date
Application number
AT97942246T
Other languages
English (en)
Inventor
Koichiro Ono
Toshihiko Ohtomo
Masayuki Tsuchiya
Yasushi Yoshimura
Yasuo Koishihara
Masaaki Kosaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE512224T1 publication Critical patent/ATE512224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97942246T 1996-10-04 1997-10-03 Rekonstituierter menschlicher anti-hm.1 antikörper ATE512224T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26475696 1996-10-04
PCT/JP1997/003553 WO1998014580A1 (en) 1996-10-04 1997-10-03 Reconstituted human anti-hm1.24 antibody

Publications (1)

Publication Number Publication Date
ATE512224T1 true ATE512224T1 (de) 2011-06-15

Family

ID=17407753

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97942246T ATE512224T1 (de) 1996-10-04 1997-10-03 Rekonstituierter menschlicher anti-hm.1 antikörper

Country Status (19)

Country Link
US (2) US6699974B2 (de)
EP (1) EP0960936B1 (de)
KR (1) KR100388256B1 (de)
CN (2) CN1271205C (de)
AT (1) ATE512224T1 (de)
AU (1) AU715156B2 (de)
BR (1) BR9712488A (de)
CA (1) CA2267072C (de)
CZ (1) CZ296790B6 (de)
IL (1) IL129286A0 (de)
NO (1) NO325178B1 (de)
PL (1) PL187642B1 (de)
RU (1) RU2184147C2 (de)
SK (1) SK44399A3 (de)
TR (1) TR199900722T2 (de)
TW (1) TW530064B (de)
UA (1) UA76934C2 (de)
WO (1) WO1998014580A1 (de)
ZA (1) ZA978865B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035698A1 (en) * 1997-02-12 1998-08-20 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
KR100370744B1 (ko) * 1997-02-28 2003-02-05 츄가이 세이야꾸 가부시키가이샤 임파구의 활성화 억제제
AU732306B2 (en) * 1997-10-14 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor
JP3609026B2 (ja) * 1998-02-25 2005-01-12 中外製薬株式会社 抗ｈｍ１．２４抗体の免疫化学的測定方法
CA2343054C (en) 1998-09-18 2007-10-30 Chugai Seiyaku Kabushiki Kaisha Method for detection or measurement of plasmacytoma cells
ATE299932T1 (de) * 1999-05-10 2005-08-15 Chugai Pharmaceutical Co Ltd Verfahren der zellkultivierung
TWI290832B (en) 1999-08-23 2007-12-11 Chugai Pharmaceutical Co Ltd Expression enhancer for HM1.24 antigen
AU2001246846A1 (en) * 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
EP1354896B1 (de) * 2000-12-28 2010-02-10 Kyowa Hakko Kirin Co., Ltd. Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
EP2336149A1 (de) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Methode zur Proteinaufreinigung
US20030091574A1 (en) * 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
JP4297689B2 (ja) 2001-04-13 2009-07-15 中外製薬株式会社 抗原の発現量を定量する方法
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
PT2208784E (pt) * 2001-06-22 2013-04-03 Chugai Pharmaceutical Co Ltd Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP1541165A4 (de) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Verfahren zur stabilisierung einer proteinl sungszubereitung
ES2558303T3 (es) 2002-09-11 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
WO2005014651A1 (ja) 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
JP4794303B2 (ja) * 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤
BRPI0416262B1 (pt) * 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
EP1716181B1 (de) * 2004-02-19 2009-12-16 Genentech, Inc. Antikörper mit korrigierten cdr
WO2005095459A2 (en) * 2004-03-29 2005-10-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
KR101460932B1 (ko) * 2005-08-26 2014-11-12 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
EP2064240A2 (de) * 2006-09-18 2009-06-03 Xencor, Inc. Optimierte auf hm1.24 abzielende antikörper
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102574924A (zh) * 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
SG11201400260TA (en) 2011-09-01 2014-03-28 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
IL296754A (en) 2013-12-27 2022-11-01 Chugai Pharmaceutical Co Ltd A method for isolating an antibody with a low isoelectric point
EP3185004A4 (de) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung der viskosität einer proteinlösung
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CN111050789A (zh) 2017-06-15 2020-04-21 癌症进展有限公司 用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
EP3797752B1 (de) 2018-05-21 2024-07-17 Chugai Seiyaku Kabushiki Kaisha In einem glasbehältnis verschlossene lyophilisierte formulierung
CN115649558A (zh) 2018-05-28 2023-01-31 中外制药株式会社 填充喷嘴
JP7701913B2 (ja) 2019-10-03 2025-07-02 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
MX2024004117A (es) 2021-10-08 2024-04-19 Chugai Pharmaceutical Co Ltd Metodo para preparar formulacion de jeringa precargada.
CN119486774A (zh) 2022-04-26 2025-02-18 中外制药株式会社 含有药物制剂的内置过滤器的注射器
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
TW205553B (de) * 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO1998035698A1 (en) * 1997-02-12 1998-08-20 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
CN1277632A (zh) * 1997-10-03 2000-12-20 中外制药株式会社 天然人源化抗体
AU732306B2 (en) * 1997-10-14 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs

Also Published As

Publication number Publication date
EP0960936A4 (de) 2005-01-19
CA2267072C (en) 2004-11-30
KR100388256B1 (ko) 2003-06-19
US6699974B2 (en) 2004-03-02
CN1235639A (zh) 1999-11-17
CN1765928A (zh) 2006-05-03
PL332742A1 (en) 1999-10-11
NO991591D0 (no) 1999-03-31
CN1271205C (zh) 2006-08-23
WO1998014580A1 (en) 1998-04-09
AU715156B2 (en) 2000-01-20
BR9712488A (pt) 1999-10-19
NO325178B1 (no) 2008-02-11
AU4399297A (en) 1998-04-24
US20030045691A1 (en) 2003-03-06
RU2184147C2 (ru) 2002-06-27
SK44399A3 (en) 2000-05-16
UA76934C2 (en) 2006-10-16
CZ117399A3 (cs) 1999-09-15
KR20000048884A (ko) 2000-07-25
US20030129185A1 (en) 2003-07-10
HK1024261A1 (en) 2000-10-05
TR199900722T2 (xx) 1999-12-21
NO991591L (no) 1999-06-01
CA2267072A1 (en) 1998-04-09
EP0960936B1 (de) 2011-06-08
TW530064B (en) 2003-05-01
US7892543B2 (en) 2011-02-22
ZA978865B (en) 1998-04-20
EP0960936A1 (de) 1999-12-01
CZ296790B6 (cs) 2006-06-14
IL129286A0 (en) 2000-02-17
PL187642B1 (pl) 2004-08-31

Similar Documents

Publication Publication Date Title
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE69535243D1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
ATE373712T1 (de) Natürlicher menschlicher antikörper
IL138801A0 (en) Humanized antibody against human tissue factor and process for the preparation thereof
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
AU692100B2 (en) Reconstituted human antibody against human interleukin 6 receptor
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
EP1412388A4 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
DK0589840T3 (da) Omdannede monoklonale antistoffer mod en immunoglobulinisotype
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DK0585570T3 (da) Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties